TY  - CHAP
M1  - Book, Section
TI  - Parasitic Diseases
A1  - Cota, Jason M.
A2  - DiPiro, Joseph T.
A2  - Yee, Gary C.
A2  - Posey, L. Michael
A2  - Haines, Stuart T.
A2  - Nolin, Thomas D.
A2  - Ellingrod, Vicki
Y1  - 2020
N1  - 
T2  - Pharmacotherapy: A Pathophysiologic Approach, 11e
AB  - KEY  CONCEPTSSingle-dose  tinidazole  is  the  preferred  5-nitroimidazole  for  giardiasis  treatment.HIV-infected  patients  with  cryptosporidiosis  must  receive  antiretroviral  therapy  as  the  mainstay  of  therapy  in  addition  to  antiparasitic  therapy.Entamoeba  histolytica-specific  immunoassays  are  required  to  diagnose  amebiasis  because  stool  sample  microscopy  does  not  distinguish  between  E.  histolytica  and  the  nonpathogenic  E.  dispar.Metronidazole  and  tinidazole  are  tissue-acting  agents  against  Entamoeba;  whereas,  paromomycin  and  iodoquinol  are  luminal  amebicides.Benznidazole  is  the  only  FDA-approved  treatment  for  Chagas  disease.Chemoprophylaxis  with  non-chloroquine  antimalarial  drugs  such  as  atovaquone-proguanil  and  doxycycline  retain  effectiveness  in  areas  where  chloroquine-resistant  P.  falciparum  exposure  is  likely.Patients  with  noncalcified  parenchymal  neurocysticercosis  should  initially  receive  symptomatic  therapy  with  corticosteroids  and  antiepileptic  drugs  followed  by  antihelminthic  therapy.For  head  lice,  either  nonprescription  1%  permethrin  or  pyrethrins  plus  piperonyl  butoxide  topical  preparations  are  agents  of  choice  unless  local  resistance  to  these  agents  is  documented.A  single  application  of  5%  permethrin  results  in  cure  rates  in  more  than  90%  of  subjects  with  scabies  at  14  and  28  days,  but  a  second  dose  should  be  applied  1  week  later  because  its  ovicidal  efficacy  remains  unclear.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1182468384
ER  -